A Breakthrough Technology

An Overview

Our team of translational microbiome experts have developed a breakthrough co-culturing platform that has enabled us to generate an artificial human gut microbial community in a bioreactor – the Consortiome™.

Consortiome™ is a rationally designed microbial consortia containing more than 90% of the known gene families that are found in a healthy person’s microbiome

Overlap of gene families between
healthy donors & BiomeBank’s Consortiome™

Annotation using the NCBI COG database (”Clusters of Orthologous Genes”) identified members of 1775 gene families from a healthy donor metagenome, of which over 90% of gene families were represented in the consortium metagenome.

This technological breakthrough is revolutionary for microbial therapies. With such a diverse range of gene families, the Consortiome™ platform provides the ability to deliver therapies that have unprecedented, broad functional capability as well as highly targeted discase specific function. This provides the potential to improve efficacy compared to alternative microbiome therapies. In addition, the Consortiome™ platform eliminates the reliance on stool donors and enables BiomeBank to produce microbial therapies at scale, to large markets, and at much lower cost than other microbial products.

Our first such co-cultured therapy, BB265, targeting Ulcerative Colitis and inflammatory bowel disease, has been designed using data from use of Biomictra ™ in discovery trials and will enter human trials in 2025.



A Human First Approach to Accelerate Drug Discovery

Human discovery trials using BiomictraTM provide BiomeBank’s drug development team with real-world, human data to establish the links between key microbial communities and disease. We use advanced bioinformatic approaches to link clinical outcomes with therapeutic microbes and their functions. This ‘human-first’ approach to drug discovery allows for a more precise identification of therapeutic candidates compared to animal models of disease and minimize the risk of expensive failures.

The Development Pipeline

• BB265

BB265 is a rationally designed cultured microbiome therapy engineered for the treatment of ulcerative colitis. BB265 was developed using BiomeBank’s Consortiome platform and data from a discovery trial using BiomictraTM (donor derived) therapy in patients with active ulcerative colitis. BB265 is scheduled to enter a phase 1b/2a study in 2025.

• BB128

BB128 is a rationally designed cultured microbiome therapy engineered for the treatment of an orphan disease indication. A discovery trial in this orphan disease indication is underway using BiomictraTM.